

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/00, 31/445		A1	(11) International Publication Number: WO 99/21539 (43) International Publication Date: 6 May 1999 (06.05.99)
(21) International Application Number: PCT/US98/19357 (22) International Filing Date: 16 September 1998 (16.09.98) (30) Priority Data: 60/063,156 24 October 1997 (24.10.97) US		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): MELTZER, Leonard, Theodore [US/US]; 2906 Renfrew, Ann Arbor, MI 48105 (US). (74) Agents: RYAN, M., Andreas; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.			
(54) Title: METHOD FOR TREATING DISEASE-RELATED OR DRUG-INDUCED DYSKINESIAS			
(57) Abstract Dyskinesias in humans are treated by administering a therapeutically effective dose of an NR1A/2B site-selective NMDA receptor antagonist compound to a human suffering therefrom.			

EXPRESS MAIL NO. EV545394292US
DOCKET NO. PC26145A

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD FOR TREATING DISEASE-RELATED OR DRUG-INDUCED DYSKINESIAS

BACKGROUND OF THE INVENTION

Field of the Invention

5 This invention relates to a method for treating disease-related or drug-induced dyskinesias.

Related Background Art

Dyskinesias are debilitating motor movements that can be caused by a neurological disease, or can be drug-induced. See, for example, A.B. Joseph and R.R. Young, *Movement Disorders in Neurology and Neuropsychiatry* (Blackwell Scientific Publications, 1992), the disclosure of which is incorporated by reference herein. Disease-related dyskinesias can result from a wide range of conditions, including Wilson's disease, Huntington's disease and Sydenham's chorea. Drug-induced dyskinesias have been attributed to administration of many drugs, including drugs used in treatment of Parkinson's disease, e.g., L-DOPA, non-selective dopamine-agonists (DA-agonists), as well as DA-agonists selective for the D1, D2, D3, D4 and D5 subtypes of the dopamine receptor; and DA antagonists, especially in the case of prolonged administration of antipsychotic agents, which leads to tardive dyskinesias.

15 Drugs which act as non-selective antagonists of the N-methyl-D-aspartate (NMDA) receptor have been shown to decrease dyskinesias induced by administration of L-DOPA to primates suffering from 1,2,3,6-tetrahydro-1-methyl-4-phenylpyridine (MPTP)-induced Parkinson's disease. The NMDA receptor comprises a NR1 subunit in combination with one or more of the NR2 subunits, NR2B, NR2C or NR2D, as disclosed in Monyer et al., *Science*, Vol. 256, pages 1217-1221 (1992). K.W. Muir and K.R. Lees, *Stroke*, Vol. 26,

20

25

-2-

5 pages 503-513 (1995), discloses that administration of NMDA receptor antagonists that are NR1A/2B-site-selective leads to reduced psychotomimetic side-effects than administration of non-selective antagonists. S.M. Papa and T.N. Chase, Annals of Neurology, Vol. 39, pages 574-578 (1996), discloses that administration of the drug LY235959, available from Eli Lilly, Inc., reduced the severity of dyskinesia in monkeys being treated with L-DOPA. However, LY235959 is a non-selective NMDA receptor antagonist. It is not obvious from this work which subtype of the NMDA receptor is responsible for the antidyskinetic effect.


10 PCT International Publication No. WO 96/37226 discloses treatment of Parkinsons disease with a combination of site-selective NMDA receptor antagonist compounds and L-DOPA. Administration of the antagonist compounds allowed use of lower amounts of L-DOPA. However, there is no suggestion that NR1A/2B site-selective NMDA receptor antagonist compounds could be administered to reduce the side effects accompanying normal doses of L-DOPA.

15

SUMMARY OF THE INVENTION

20 This invention is directed to a method for treating dyskinesias, said method comprising administering to a human suffering therefrom a therapeutically effective amount of a NR1A/2B-site-selective NMDA receptor antagonist compound.

In a preferred embodiment of this invention, the compound is



-3-

or a pharmaceutically acceptable salt thereof wherein

Ar¹ and Ar² are independently aryl or a heteroaryl group, either of which may be independently substituted by one to three of hydroxy, alkyl, halogen, nitro, cyano, carboxaldehyde, aldehyde oxime, lower alkoxy carbonylmethyl, hydroxy lower alkyl, aminocarbonylmethyl, hydrazinocarbonylmethyl, acetamido, aryl, aralkyl, amino, a halogenated alkyl group, a lower alkyl amino group or a lower alkoxy group;

X is -(CHR³)_m-, wherein each R³ is independently hydrogen, hydroxy, or a lower alkyl group having 1 to 6 carbon atoms; and m is 0 or 1;


10 each R² is independently hydrogen, hydroxy or a lower alkyl group having 1 to 6 carbon atoms;

n is 1, 2, 3 or 4;

Y is C≡C, O, SO_p wherein p is 0, 1 or 2, NR⁴ wherein R⁴ is hydrogen or a lower alkyl group having 1 to 6 carbon atoms, or a single bond; and


15 R⁵ is hydrogen or hydroxy.

In another preferred embodiment, the compound has a structure selected from those listed below, their stereoisomers, and their pharmaceutically acceptable salts:




20 α-(4-chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol;


-4-




α -(4-hydroxyphenyl)- β -methyl-4-(phenylmethyl)-1-piperidineethanol;



4-hydroxy- α -(4-hydroxyphenyl)- β -methyl-4-phenyl-1-piperidineethanol;



3-[4-(4-phenyl)-4-hydroxypiperidin-1-yl]-chroman-4,7-diol; and



α -(4-hydroxyphenyl)- β -methyl-4-(phenylmethyl)-1-piperidinepropanol.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph showing the duration of L-DOPA response for L-DOPA in combination with varying doses of a NR1A/2B site-selective NMDA antagonist.


5 Figure 2 is a graph showing the magnitude of the anti-Parkinsonian response for L-DOPA in combination with varying doses of a NR1A/2B site-selective NMDA antagonist.

Figure 3 is a graph showing the magnitude of locomotor activity for L-DOPA in combination with varying doses of a NR1A/2B site-selective NMDA antagonist.

10 Figure 4 is a graph showing the sum of all dyskinesia scores as a percentage of the duration of L-DOPA response for L-DOPA in combination with varying doses of a NR1A/2B site-selective NMDA antagonist.

DETAILED DESCRIPTION OF THE INVENTION

15 In the method of this invention, dyskinesias are treated by administration of a therapeutically effective amount of a NR1A/2B-site-selective NMDA receptor antagonist compound. Preferably, this invention employs a compound having the structure:



20 or a stereoisomer or pharmaceutically acceptable salt thereof wherein Ar^1 and Ar^2 are independently aryl or a heteroaryl group, either of which may be independently substituted by one to three of hydroxy, alkyl, halogen, nitro, cyano, carboxaldehyde, aldehyde oxime, lower alkoxy carbonylmethyl, hydroxy lower

-6-

alkyl, aminocarbonylmethyl, hydrazinocarbonylmethyl, acetamido, aryl, aralkyl, amino, a halogenated alkyl group, a lower alkyl amino group or a lower alkoxy group;

5 X is $-(CHR^3)_m-$, wherein each R^3 is independently hydrogen, hydroxy or a lower alkyl group having 1 to 6 carbon atoms; and m is 0 or 1;

each R^2 is independently hydrogen, hydroxy or a lower alkyl group having 1 to 6 carbon atoms;


n is 1, 2, 3 or 4;

10 Y is $C\equiv C$, O, SO_p wherein p is 0, 1 or 2, NR^4 wherein R^4 is hydrogen or a lower alkyl group having 1 to 6 carbon atoms, or a single bond; and

R^5 is hydrogen or hydroxy,


which are disclosed in PCT International Publication Nos. WO 97/23216 and WO 97/23214, the disclosures of which are incorporated by reference herein.

15 In another preferred embodiment of this invention, the compound administered is selected from the compounds having the structures and names listed below, their stereoisomers, and their pharmaceutically acceptable salts:




α -(4-chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol (Eliprodil, available from Synthelabo, Inc., and disclosed in U.S. Patent No. 5,547,963)


-7-



α -(4-hydroxyphenyl)- β -methyl-4-(phenylmethyl)-1-piperidineethanol (Ifenprodil, available from Synthelabo, Inc., and disclosed in U.S. Patent No. 3,509,164)




5 4-hydroxy- α -(4-hydroxyphenyl)- β -methyl-4-phenyl-1-piperidineethanol
(optically active form CP-101,606, available from Pfizer, Inc., and disclosed in U.S. Patent No. 5,272,160).



10 3-[4-(4-phenyl)-4-hydroxypiperidin-1-yl]-chroman-4,7-diol (optically active form CP-283,097, available from Pfizer, Inc.)


-8-



12


α -(4-hydroxyphenyl)- β -methyl-4-(phenylmethyl)-1-piperidinepropanol (optically active form Ro 25-6981, available from Hoffmann-La Roche, and disclosed in European Patent Application No. EP 648,744).

5 The most preferred compounds for administration in the method of this invention are 1-[2-(4-hydroxyphenoxy)ethyl]-4-hydroxy-4-(4-methylbenzyl) piperidine hydrochloride, which has the following structure:



13


10 and 1-[2-(4-Hydroxyphenoxy)ethyl]-4-(4-fluorobenzyl)-4-hydroxy-piperidine hydrochloride, which has the following structure:



14

and CP-101,606, [S-(R*,R*)]-4-hydroxy- α -(4-hydroxyphenyl)- β -methyl-4-phenyl-1-piperidineethanol, which has the following structure:

-9-



and is described in PCT Application No. WO 96/37226, the disclosure of which is incorporated by reference herein.

Also included within the scope of the present invention is the use of the non-toxic pharmaceutically acceptable salts of the compounds described herein. Acid addition salts are formed by mixing a solution of the particular compound used in the present invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, and the like.

The pharmaceutical compositions of the present invention may be administered by any means that achieve their intended purpose. For example, administration may be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.


Suitable dosage levels in the method of this invention for oral administration range from about 100 mg/dose to about 1000 mg/dose. For subcutaneous administration, the suitable level is from about 1 mg/dose to about 200 mg/dose.

-10-

The examples which follow are intended as illustrations of certain preferred embodiments of the invention, and no limitation of the invention is implied.

EXAMPLE 1

1-[2-(4-Hydroxyphenoxy)ethyl]-4-hydroxy-4-(4-methylbenzyl)piperidine hydrochloride



16

A) 1-Benzyl-4-hydroxy-4-(4-methylbenzyl)piperidine. To a 250-mL three-necked round-bottomed flask was added 2.31 g of Mg turnings and 15 mL of anhydrous THF under N_2 . To which was added dropwise a solution of 1,2-dibromoethane (0.489 g, 2.65 mmol) in 5 mL of THF at rt. After addition, THF was removed, and the residue was rinsed with THF (2×5 mL). To this residue was added dropwise a solution of 4-methylbenzyl chloride (13.0 g, 92.6 mmol) in 50 mL of THF at 0°C. After addition, the solution was allowed to stir at rt for 2 h and another 50 mL of THF was added. After cooling down to -35°C to -40°C, a solution of 4-benzylpiperidone (5.0 g, 26.5 mmol) in 20 mL of THF was added dropwise. After the addition was complete, the reaction mixture was allowed to stir at rt for 3 h and stand overnight. To this reaction mixture was added 100 mL of saturated NH_4Cl aqueous solution at 0°C and then extracted with dichloromethane (2×50 mL). The combined organic phase was evaporated *in vacuo* to give an oil, which was redissolved into 200 mL of dichloromethane and washed with saturated NH_4Cl aqueous solution (2×30 mL) and brine (50 mL), and then dried over sodium sulfate. Evaporation of solvent followed by flash chromatography (EtOAc $R_f = 0.25$), giving 7.5 g (96%) of the product as a pale yellow oil.

-11-

¹H NMR (CDCl₃): 1.476 (m, 2 H), 1.725 (m, 2 H), 2.046 (s, 1 H), 2.323 (m, 5 H), 2.611 (m, 2 H), 2.713 (s, 2 H), 3.505 (s, 2 H), 7.086 (m, 4 H), 7.299 (m, 5 H).

B) 4-Hydroxy-4-(4-methylbenzyl)piperidine hydrochloride. A mixture of 1-benzyl-4-(4-methylbenzyl)-4-hydroxypiperidine (2.8 g, 9.5 mmol) and 700 mg of 10% Pd/C in 100 mL of 95% ethanol was hydrogenated at 50 psi for overnight. The catalyst was removed through a short column of celite (10 g) and washed with methanol (3 × 15 mL). To the filtrate was added 12 mL of 1M HCl in methanol. Evaporation of methanol gave a residue, to which was added 30 mL of ether. The mixture was stirred at rt for 2 days. A white solid was collected by filtration, giving 2.1 g (92%) of the title product: mp 183-185°C. ¹H NMR (CDCl₃): 1.680 (m, 2 H), 2.097 (m, 2 H), 2.338 (s, 3 H), 2.783 (s, 2 H), 3.241 (m, 5 H), 7.049 (d, J = 7.5 Hz, 2 H), 7.142 (d, J = 7.5 Hz, 2 H), 9.30 (brs, 1 H), 9.515 (brs, 1 H).

C) 1-[2-(4-Benzylxyphenoxy)ethyl]-4-hydroxy-4-(4-methylbenzyl) piperidine hydrochloride. A mixture of 2-(4-benzylxyphenoxy)ethyl bromide (368 mg, 1.2 mmol), 4-(4-methylbenzyl)-4-hydroxypiperidine hydrochloride (290 mg, 1.2 mmol), potassium carbonate (414 mg, 3 mmol) in 30 mL of acetonitrile was allowed to reflux for 12 h. The inorganic salt was removed through a short column of silica gel and washed with ethyl acetate (3 × 25 mL). The combined filtrate was evaporated *in vacuo* to give a crude mixture, which was purified by flash chromatography (5% methanol in ethyl acetate), giving a pale yellow oil, which was dissolved into methanol (10 mL), to which was added 4 mL of 1 M HCl in methanol. The resulting solution was allowed to stir at rt for 10 min, and methanol was evaporated in *vacuo* to give a residue, to which 50 mL of ether was added. The resulting mixture was stirred overnight. A white solid was collected by filtration and dried *in vacuo*, giving 420 mg (75%) of the title product: mp 179-181°C.

¹H NMR (CDCl₃): 1.605 (s, 2 H), 1.725 (d, J = 14.1 Hz, 2 H), 2.332 (s, 3 H), 2.453 (m, 2 H), 2.809 (s, 2 H), 3.221 (m, 2 H), 3.361 (s, 1 H), 3.464 (d, J = 8.4 Hz, 2 H), 4.488 (s, 2 H), 5.005 (s, 2 H), 6.820 (d, J = 9.0 Hz, 2 H), 6.904 (d,

-12-

$J = 9.0$ Hz, 2 H), 7.077 (d, $J = 7.5$ Hz, 2 H), 7.166 (d, $J = 7.5$ Hz, 2 H), 7.376 (m, 5 H), 12.4 (bs, 1 H).


D) 1-[2-(4-Hydroxyphenoxy)ethyl]-4-hydroxy-4-(4-methylbenzyl)piperidine hydrochloride. To a solution of 1-[2-(4-benzyloxyphenoxy)ethyl]-4-hydroxy-4-(4-methylbenzyl)piperidine hydrochloride (0.25 g, 0.53 mmol) in 30 mL of methanol was added 62.5 mg of 20% $Pd(OH)_2$. The resulting mixture was hydrogenated at 20 psi of hydrogen for 3 h. The catalyst was removed through a short column of celite (5 g) and washed with methanol (3 \times 15 mL). Methanol was evaporated *in vacuo* to give a residue, to which 50 mL of ether was added. The resulting mixture was stirred overnight. A white solid was collected by filtration and dried *in vacuo*, giving 200 mg (100%) of the title product: mp 133-135°C.

10 1H NMR (CD_3OD): 1.58 (m, 2 H), 1.75 (m, 2 H), 2.119 (s, 3 H), 2.615 (s, 2 H), 3.20-3.30 (m, 6 H), 4.056 (m, 2 H), 6.528 (d, $J = 9.0$ Hz, 2 H), 6.645 (d, $J = 9.0$ Hz, 2 H), 6.938 (s, 4 H).

15

EXAMPLE 2

1-[2-(4-Hydroxyphenoxy)ethyl]-4-(4-fluorobenzyl)-4-hydroxypiperidine hydrochloride



17

A) 1-[2-(4-Benzyloxyphenoxy)ethyl]-4-(4-fluorobenzyl)-4-hydroxypiperidine.

20 A mixture of 2-(4-benzyloxyphenoxy)ethyl bromide (1.075 g, 3.5 mmol), 4-(4-fluorobenzyl)-4-hydroxypiperidine (0.778 g, 3.7 mmol), potassium carbonate (1.28 g, 9.25 mmol) in 50 mL of acetonitrile was allowed to reflux for 12 h. The inorganic salt was removed through a short column of silica gel and washed with ethyl acetate (3 \times 25 mL). The combined filtrate was evaporated *in vacuo* to give a

-13-

crude product, which was purified by flash chromatography (5% methanol in ethyl acetate), giving 0.8 g (53%) of the title compound as a pale yellow oil.

¹H NMR (CDCl₃) 1.544 (m, 2 H), 1.80 (m, 2 H), 2.50 (m, 2 H), 2.834 (m, 3 H), 3.484 (s, 4 H), 4.079 (t, J = 4.8 Hz, 2 H), 5.008 (s, 2 H), 6.810 (d, J = 9.0 Hz, 2 H), 6.878 (d, J = 9.0 Hz, 2 H), 6.997 (m, 2 H), 7.135 (m, 2 H), 7.350 (m, 5 H).

B) 1-[2-(4-Hydroxyphenoxy)ethyl]-4-(4-fluorobenzyl)-4-hydroxypiperidine hydrochloride. To a solution of 1-[2-(4-benzyloxyphenoxy)ethyl]-4-(4-fluorobenzyl)-4-hydroxypiperidine (0.8 g, 1.8 mmol) in 25 mL of methanol was added 200 mg of 20% Pd(OH)₂. The resulting mixture was hydrogenated at 20 psi of hydrogen for 3 h. The catalyst was removed through a short column of celite (5 g) and washed with methanol (3 × 15 mL), to which was added 4 mL of 1 M HCl in methanol. The resulting solution was allowed to stir at rt for 10 min. and methanol was evaporated *in vacuo* to give a residue, to which 50 mL of ether was added. The resulting mixture was stirred overnight. A white solid was collected by filtration and dried *in vacuo*, giving 550 mg (80%) of the title compound: mp 128-130°C. ¹H NMR (CD₃OD): 1.732 (m, 2 H), 1.935 (m, 2 H), 2.825 (m, 2 H), 3.328 (m, 2 H), 3.486 (m, 4 H), 4.265 (s, 2 H), 6.719 (m, 2 H), 6.840 (m, 2 H), 7.033 (m, 2 H), 7.238 (m, 2 H). Anal. Calcd for C₂₀H₂₅ClFNO₃·0.5H₂O: C, 61.46; H, 6.70; N, 3.58. Found: C, 61.50; H, 6.64; N, 3.59.

EXAMPLE 3

Administration of L-DOPA and the Compound of Example 1 to MPTP-Treated Monkeys

The subjects were 6 cynomolgus monkeys that had stable Parkinson signs induced by treatment with 0.5 mg/kg 1,2,3,6-tetrahydro-1-methyl-4-phenylpyridine (MPTP) once weekly until development of stable signs occurred. Six weeks after MPTP treatment ended, daily L-DOPA administration was performed for 3-4 weeks until dyskinetic movements had been induced. The treatment dose of L-DOPA was adjusted for each individual monkey. The therapeutic anti-


5 Parkinsonian effect, as well as the dyskinetic effect is different for each monkey. The dose of L-DOPA used was what was effective for each animal. In response to L-DOPA, the monkeys show the expected therapeutic response, i.e., improved motor function, as well as motor side-effects and dyskinesias, that are observed in humans suffering from idiopathic Parkinson's disease.

10 The behavioral effects of L-DOPA alone and in combination with the compound of Example 1 were determined. Both compounds were administered subcutaneously (SC). When co-administered with an effective dose of L-DOPA, the compound of Example 1 at levels of 0.01, 0.1, 1.0 and 2.5 mg/kg SC did not alter the duration in minutes of the L-DOPA-induced behavioral response, as shown in Figure 1. The magnitude of the peak anti-Parkinsonian response, in terms of points on an improvement scale response, was also unaffected, as shown in Figure 2, as was locomotor activity, as measured by activity monitors, as shown in Figure 3. Administration of the compound of Example 1 reduced, in a dose-15 response manner, the induction of the L-DOPA-induced dyskinesias, as shown in Figure 4. Thus, the monkeys retained the therapeutic effects of the L-DOPA, but experienced lessened dyskinetic side-effects.

20 Other variations and modifications of this invention will be obvious to those skilled in this art. This invention is not limited except as set forth in the following claims.

CLAIMS

1. A method for treating dyskinesias, said method comprising administering to a human suffering therefrom a therapeutically effective amount of a NR1A/2B site-selective NMDA receptor antagonist compound.
- 5 2. The method of Claim 1, wherein the compound has the structure



or a stereoisomer or pharmaceutically acceptable salt thereof wherein

10 Ar^1 and Ar^2 are independently aryl or a heteroaryl group, either of which may be independently substituted by one to three of hydroxy, alkyl, halogen, nitro, cyano, carboxaldehyde, aldehyde oxime, lower alkoxy carbonylmethyl, hydroxy lower alkyl, aminocarbonylmethyl, hydrazinocarbonylmethyl, acetamido, aryl, aralkyl, amino, a halogenated alkyl group, a lower alkyl amino group or a lower alkoxy group;

15 X is $-(\text{CHR}^3)_m-$, wherein each R^3 is independently hydrogen, hydroxy or a lower alkyl group having 1 to 6 carbon atoms; and m is 0 or 1;

each R^2 is independently hydrogen, hydroxy or a lower alkyl group having 1 to 6 carbon atoms;





n is 1, 2, 3 or 4;

-16-


Y is C≡C, O, SO_p wherein p is 0, 1 or 2, NR⁴ wherein R⁴ is hydrogen or a lower alkyl group having 1 to 6 carbon atoms, or a single bond; and

R⁵ is hydrogen or hydroxy.

3. The method of Claim 1, wherein the compound is selected from the group consisting of



-17-




23

and their stereoisomers and pharmaceutically acceptable salts.

4. The method of Claim 2, wherein the compound is 1-[2-(4-hydroxyphenoxy)ethyl]-4-hydroxy-4-(4-methylbenzyl)piperidine hydrochloride.
5. The method of Claim 2, wherein the compound is 1-[2-(4-Hydroxyphenoxy)ethyl]-4-(4-fluorobenzyl)-4-hydroxy-piperidine hydrochloride.
6. The method of Claim 3, wherein the compound is [S-(R*,R*)]-4-hydroxy- α -(4-hydroxyphenyl)- β -methyl-4-phenyl-1-piperidineethanol.
7. A method for reducing dyskinesias in treatment Parkinson's disease, said method comprising administering to a human suffering therefrom a therapeutically effective amount of a NR1A/2B site-selective NMDA receptor antagonist compound.

10

FIG-1 Duration of the L-Dopa response in min

2/4

FIG-2 Magnitude of the antiparkinsonian response






FIG-3 PAM activity

4/4

FIG-4 Dyskinesia Severity Index (DSI)

INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 98/19357

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/00 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 96 37226 A (PFIZER ;CHENARD BERTRAND L (US); MENNITI FRANK S (US)) 28 November 1996 cited in the application see abstract see page 1, line 20 - page 2, line 5 see page 3, line 16 - page 7, line 9; claims; examples</p> <p>---</p> <p>B. COSTALL ET AL.: "DOPAMINE ANTAGONIST EFFECTS OF A SERIES OF ANALOGUES OF OXIPEROMIDE AND SPIROXATRINE MEASURED BEHAVIOURALLY IN THE RODENT" J. PHARM. PHARMACOL., vol. 30, no. 11, 1978, pages 693-698, XP002090025 see the whole document</p> <p>---</p> <p style="text-align: right;">-/-</p>	1-3,6,7
X		1,2

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 January 1999

Date of mailing of the international search report

03/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo rd.
Fax: (+31-70) 340-3016

Authorized officer

Hoff, P

INTERNATIONAL SEARCH REPORT

dional Application No	
PCT/US 98/19357	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 364 867 A (DEHAVEN-HUDKINS DIANE L ET AL) 15 November 1994 see abstract see example 3 see column 11, line 58 - line 66; claims ---	1,2
X	WO 93 00313 A (UNIV VIRGINIA COMMONWEALTH) 7 January 1993 see abstract see page 38, line 14 - line 30 see page 68 compounds 39,40 see page 81 compound 81 see page 98 compound 148 see claims 15,17,21,22 ---	1,2
X	EP 0 673 933 A (ADIR) 27 September 1995 see abstract see page 6, line 9 - line 11; claims; examples 1-10,20-29 ---	1,2
X	WO 93 22310 A (DU PONT MERCK PHARMA) 11 November 1993 see abstract see page 23, line 1 - line 11; claims 44,87; examples; tables 1,3,4 ---	1,2
X	WO 91 06297 A (DU PONT) 16 May 1991 see abstract see page 15, line 13 - line 19; claim 87; examples; tables ---	1,2
X	"THE MERCK INDEX" 1996 , MERCK & CO , WHITEHOUSE STATION, NJ XP002090029 "Haloperidol" see page 785 ---	1
A	L.L. COUGHENOUR ET AL.: "CHARACTERIZATION OF HALOPERIDOL AND TRIFLUPERIDOL AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE NMDA RECEPTOR ANTAGONISTS USING (3H)TCP AND (3H)IFENPRODIL BINDING IN RAT BRAIN MEMBRANES" J. PHARMACOL. EXP. THER., vol. 280, no. 2, February 1997, pages 584-592, XP002090026 see the whole document ---	1
A	WO 97 23216 A (BIGGE CHRISTOPHER F ;WARNER LAMBERT CO (US); CAI SUI XIONG (US); L) 3 July 1997 cited in the application see abstract; claims; examples 123,154 ---	1,2,4,5, 7
		-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/19357

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	S.M. PAPA ET AL.: "LEVODOPA-INDUCED DYSKINESIA IMPROVED BY A GLUTAMATE ANTAGONIST IN PARKINSONIAN MONKEYS" ANNALS OF NEUROLOGY, vol. 39, 1996, pages 574-578, XP002090027 cited in the application see the whole document ----	1-7
A	JL MONTASTRUCC ET AL.: "A PILOT STUDY OF N-METHYL-D-ASPARTATE (NMDA) ANTAGONIST IN PARKINSON'S DISEASE" J. NEUROL. NEUROSURG. PSYCHIATRY, vol. 55, no. 7, 1992, pages 630-631, XP002090028 see the whole document ----	1-7
A	EP 0 449 186 A (DU PONT MERCK PHARMA) 2 October 1991 see the whole document -----	1-7

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/19357

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-7 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

In view of the large number of compounds which are theoretically contained within the definition "NR1A/2B site-selective NMDA receptor antagonist" of claims 1 and 7, the search had to be restricted on economic grounds to the general idea of the invention and to the compounds mentioned in claims 3 to 6 (Art.6 PCT; Guidelines Chapt.II.7 last sentence and Chapt.III,3.7). Claims searched completely: 3-6

Claims searched incompletely: 1,2,7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/19357

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9637226	A 28-11-1996	AU 696258 B AU 5451996 A BR 9602485 A CN 1159325 A CZ 9601524 A EP 0828513 A FI 974323 A NO 962130 A PL 314413 A SG 45479 A		03-09-1998 05-12-1996 22-04-1998 17-09-1997 15-04-1998 18-03-1998 25-11-1997 27-11-1996 09-12-1996 16-01-1998
US 5364867	A 15-11-1994	NONE		
WO 9300313	A 07-01-1993	AU 676993 B AU 2294592 A CA 2111957 A EP 0591426 A JP 6509069 T PT 100639 A ZA 9204775 A		10-04-1997 25-01-1993 07-01-1993 13-04-1994 13-10-1994 30-09-1993 16-04-1993
EP 0673933	A 27-09-1995	FR 2717810 A AU 680717 B AU 1498895 A CA 2145026 A CN 1112114 A FI 951297 A JP 2705788 B JP 7258233 A NO 951081 A NZ 270760 A US 5534511 A US 5688811 A US 5688820 A ZA 9502333 A		29-09-1995 07-08-1997 28-09-1995 23-09-1995 22-11-1995 23-09-1995 28-01-1998 09-10-1995 25-09-1995 26-03-1996 09-07-1996 18-11-1997 18-11-1997 15-12-1995
WO 9322310	A 11-11-1993	US 5356906 A AU 4034593 A US 5480892 A		18-10-1994 29-11-1993 02-01-1996
WO 9106297	A 16-05-1991	AU 655406 B EP 0497843 A FI 921856 A IL 96144 A JP 6504980 T US 5480892 A US 5356906 A		22-12-1994 12-08-1992 24-04-1992 24-06-1994 09-06-1994 02-01-1996 18-10-1994
WO 9723216	A 03-07-1997	AU 1689997 A CA 2240275 A EP 0869792 A NO 982870 A		17-07-1997 03-07-1997 14-10-1998 24-08-1998
EP 0449186	A 02-10-1991	US 5116846 A CA 2038681 A JP 4364164 A		26-05-1992 29-09-1991 16-12-1992